
AcelRx Pharmaceuticals ACRX
Quarterly report 2025-Q3
added 11-12-2025
AcelRx Pharmaceuticals EV/EBITDA Ratio 2011-2026 | ACRX
Annual EV/EBITDA Ratio AcelRx Pharmaceuticals
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| -2.97 | -4.66 | -2.79 | -1.93 | -1.56 | -1.97 | -4.24 | -6.96 | -64.5 | -2.79 | -3.08 |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -1.56 | -64.5 | -8.86 |
EV/EBITDA Ratio of other stocks in the Drug manufacturers industry
| Issuer | EV/EBITDA Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Aerie Pharmaceuticals
AERI
|
-18.4 | - | - | $ 754 M | ||
|
Agile Therapeutics
AGRX
|
-18.5 | - | 10.11 % | $ 58.2 M | ||
|
Avadel Pharmaceuticals plc
AVDL
|
-6.92 | - | 0.12 % | $ 2.06 B | ||
|
Alimera Sciences
ALIM
|
4.15 | - | - | $ 142 M | ||
|
Adamis Pharmaceuticals Corporation
ADMP
|
0.353 | - | 0.86 % | $ 117 M | ||
|
Canopy Growth Corporation
CGC
|
-4.28 | - | -3.21 % | $ 114 M | ||
|
Cronos Group
CRON
|
-14.5 | - | -1.32 % | $ 1.35 B | ||
|
Catalent
CTLT
|
22.8 | - | - | $ 11.5 B | ||
|
Eagle Pharmaceuticals
EGRX
|
160 | - | -39.89 % | $ 27.7 M | ||
|
Endo International plc
ENDP
|
-1.77 | - | - | $ 28.9 M | ||
|
Cumberland Pharmaceuticals
CPIX
|
-19.4 | - | 1.17 % | $ 55 M | ||
|
Calliditas Therapeutics AB (publ)
CALT
|
-0.0195 | - | -0.1 % | $ 2.03 B | ||
|
HEXO Corp.
HEXO
|
-1.44 | - | 2.45 % | $ 38.1 M | ||
|
Evoke Pharma
EVOK
|
-27.4 | - | - | $ 36.6 M | ||
|
DURECT Corporation
DRRX
|
1.47 | - | - | $ 50.1 M | ||
|
Emergent BioSolutions
EBS
|
7.77 | $ 11.07 | - | $ 567 M | ||
|
Athenex
ATNX
|
-1.1 | - | -23.39 % | $ 1.76 M | ||
|
Jupiter Wellness
JUPW
|
-50.5 | - | - | $ 33.6 M | ||
|
Evolus
EOLS
|
-9.74 | $ 4.35 | - | $ 270 M | ||
|
China Pharma Holdings
CPHI
|
51.8 | - | -2.39 % | $ 11.4 M | ||
|
Harrow Health
HROW
|
72.8 | $ 49.44 | 3.63 % | $ 1.61 B | ||
|
Pacira BioSciences
PCRX
|
29.6 | $ 21.69 | 2.05 % | $ 1 B | ||
|
Perrigo Company plc
PRGO
|
11.2 | $ 14.49 | 0.59 % | $ 1.99 B | ||
|
OrganiGram Holdings
OGI
|
-2.79 | $ 1.33 | - | $ 402 M | ||
|
Lannett Company
LCI
|
-3.47 | - | 1.15 % | $ 7.11 M | ||
|
Bausch Health Companies
BHC
|
18.6 | - | - | $ 2.22 B | ||
|
Sundial Growers
SNDL
|
-1.27 | $ 1.51 | 1.01 % | $ 3.37 M | ||
|
Tilray
TLRY
|
-46 | $ 7.54 | - | $ 4.66 B | ||
|
Neoleukin Therapeutics
NLTX
|
0.202 | - | - | $ 193 M | ||
|
Organogenesis Holdings
ORGO
|
15.8 | - | -2.73 % | $ 492 M | ||
|
cbdMD
YCBD
|
-2.7 | $ 0.75 | -6.86 % | $ 3.23 M | ||
|
PetIQ
PETQ
|
9.82 | - | 1.64 % | $ 400 M | ||
|
Aurora Cannabis
ACB
|
-2.99 | - | -3.23 % | $ 86.3 M | ||
|
ProPhase Labs
PRPH
|
9.86 | - | - | $ 5.07 M | ||
|
Radius Health
RDUS
|
-13.2 | - | - | $ 1.42 B | ||
|
Recro Pharma
REPH
|
13.4 | - | -4.76 % | $ 65.3 M | ||
|
Rockwell Medical
RMTI
|
-13.7 | $ 1.08 | -1.38 % | $ 25.2 M | ||
|
Relmada Therapeutics
RLMD
|
-2.91 | - | - | $ 120 M | ||
|
OptiNose
OPTN
|
-2.04 | - | - | $ 1.08 B | ||
|
Assertio Holdings
ASRT
|
7.11 | - | 2.31 % | $ 849 M | ||
|
PLx Pharma
PLXP
|
-1.81 | - | -27.8 % | $ 2.56 M | ||
|
Sonoma Pharmaceuticals
SNOA
|
-4.16 | - | - | $ 3.52 M | ||
|
Solid Biosciences
SLDB
|
-0.17 | - | - | $ 261 M | ||
|
SCYNEXIS
SCYX
|
-1.32 | $ 0.81 | - | $ 38.8 M | ||
|
Veru
VERU
|
31.2 | - | 3.03 % | $ 321 M | ||
|
Tricida
TCDA
|
-3.32 | - | - | $ 3.25 M | ||
|
TherapeuticsMD
TXMD
|
-45.5 | $ 2.32 | -2.52 % | $ 24.2 M | ||
|
Viatris
VTRS
|
10.5 | - | - | $ 19.4 B | ||
|
Zynerba Pharmaceuticals
ZYNE
|
-0.574 | - | - | $ 55.5 M |